{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:18:52Z","timestamp":1694650732988},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T00:00:00Z","timestamp":1358208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1038\/nrurol.2012.257","type":"journal-article","created":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T10:50:12Z","timestamp":1358247012000},"page":"116-122","source":"Crossref","is-referenced-by-count":2,"title":["Familial prostate cancer: the damage done and lessons learnt"],"prefix":"10.1038","volume":"10","author":[{"given":"Nassim","family":"Taherian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Hamel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis R.","family":"B\u00e9gin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek A.","family":"Bismar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Goldgar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing-Jian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Foulkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,1,15]]},"reference":[{"key":"BFnrurol2012257_CR1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1086\/302099","volume":"63","author":"PN Tonin","year":"1998","unstructured":"Tonin, P. N.  et al. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am. J. Hum. Genet. 63, 1341\u20131451 (1998).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrurol2012257_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/1097-0215(20010520)95:3<189::AID-IJC1032>3.0.CO;2-N","volume":"95","author":"PN Tonin","year":"2001","unstructured":"Tonin, P. N.  et al. Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history. Int. J. Cancer 95, 189\u2013193 (2001).","journal-title":"Int. J. Cancer"},{"key":"BFnrurol2012257_CR3","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1038\/bjc.2012.87","volume":"106","author":"DJ Osher","year":"2012","unstructured":"Osher, D. J.  et al. Mutation analysis of RAD51D in non-BRCA1\/2 ovarian and breast cancer families. Br. J. Cancer 106, 1460\u20131463 (2012).","journal-title":"Br. J. Cancer"},{"key":"BFnrurol2012257_CR4","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1073\/pnas.81.11.3443","volume":"81","author":"GM Lathrop","year":"1984","unstructured":"Lathrop, G. M., Lalouel, J. M., Juliel, C. & Ott, J. Strategies for multilocus linkage analysis in humans. Proc. Natl Acad. Sci. USA 81, 3443\u20133446 (1984).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrurol2012257_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/345310","volume":"72","author":"SM Edwards","year":"2003","unstructured":"Edwards, S. M.  et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am. J. Hum. Genet. 72, 1\u201312 (2003).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrurol2012257_CR6","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/ng.450","volume":"41","author":"RA Eeles","year":"2009","unstructured":"Eeles, R. A.  et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet. 41, 1116\u20131121 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrurol2012257_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ng.91","volume":"40","author":"G Thomas","year":"2008","unstructured":"Thomas, G.  et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet. 40, 310\u2013315 (2008).","journal-title":"Nat. Genet."},{"key":"BFnrurol2012257_CR8","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/ng.452","volume":"41","author":"AA Al Olama","year":"2009","unstructured":"Al Olama, A. A.  et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat. Genet. 41, 1058\u20131060 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrurol2012257_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/ng.90","volume":"40","author":"RA Eeles","year":"2008","unstructured":"Eeles, R. A.  et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 40, 316\u2013321 (2008).","journal-title":"Nat. Genet."},{"key":"BFnrurol2012257_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa1110000","volume":"366","author":"CM Ewing","year":"2012","unstructured":"Ewing, C. M.  et al. Germline mutations in HOXB13 and prostate-cancer risk. N. Engl. J. Med. 366, 141\u2013149 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol2012257_CR11","unstructured":"Canadian Cancer Society. Canadian Cancer Statistics 2011 \n                    [online]\n                    \n                  , (2011)."},{"key":"BFnrurol2012257_CR12","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/jnci\/djp278","volume":"101","author":"HG Welch","year":"2009","unstructured":"Welch, H. G. & Albertsen, P. C. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986\u20132005. J. Natl Cancer Inst. 101, 1325\u20131329 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrurol2012257_CR13","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1002\/cncr.24324","volume":"115","author":"DW Lin","year":"2009","unstructured":"Lin, D. W., Porter, M. & Montgomery, B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a population based cohort study. Cancer 115, 2863\u20132871 (2009).","journal-title":"Cancer"},{"key":"BFnrurol2012257_CR14","doi-asserted-by":"publisher","first-page":"R103","DOI":"10.1093\/hmg\/ddh072","volume":"13","author":"DJ Schaid","year":"2004","unstructured":"Schaid, D. J. The complex genetic epidemiology of prostate cancer. Hum. Mol. Genet. 13, R103\u2013R121 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrurol2012257_CR15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0022-5347(17)35617-3","volume":"150","author":"BS Carter","year":"1993","unstructured":"Carter, B. S.  et al. Hereditary prostate cancer: epidemiologic and clinical features. J. Urol. 150, 797\u2013802 (1993).","journal-title":"J. Urol."},{"key":"BFnrurol2012257_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/oxfordjournals.aje.a009313","volume":"146","author":"H Gr\u00f6nberg","year":"1997","unstructured":"Gr\u00f6nberg, H., Damber, L., Damber, J. E. & Iselius, L. Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am. J. Epidemiol. 146, 552\u2013557 (1997).","journal-title":"Am. J. Epidemiol."},{"key":"BFnrurol2012257_CR17","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1086\/301862","volume":"62","author":"DJ Schaid","year":"1998","unstructured":"Schaid, D. J., McDonnell, S. K., Blute, M. L. & Thibodeau, S. N. Evidence for autosomal dominant inheritance of prostate cancer. Am. J. Hum. Genet. 62, 1425\u20131438 (1998).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrurol2012257_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0090-4295(00)00891-8","volume":"57","author":"BA Verhage","year":"2001","unstructured":"Verhage, B. A.  et al. Autosomal dominant inheritance of prostate cancer: a confirmatory study. Urology 57, 97\u2013101 (2001).","journal-title":"Urology"},{"key":"BFnrurol2012257_CR19","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1126\/science.274.5291.1371","volume":"274","author":"JR Smith","year":"1996","unstructured":"Smith, J. R.  et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274, 1371\u20131374 (1996).","journal-title":"Science"},{"key":"BFnrurol2012257_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s004390100488","volume":"108","author":"J Xu","year":"2001","unstructured":"Xu, J.  et al. Linkage of prostate cancer susceptibility loci to chromosome 1. Hum. Genet. 108, 335\u2013345 (2001).","journal-title":"Hum. Genet."},{"key":"BFnrurol2012257_CR21","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1086\/301879","volume":"62","author":"P Berthon","year":"1998","unstructured":"Berthon, P.  et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2\u201343. Am. J. Hum. Genet. 62, 1416\u20131424 (1998).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrurol2012257_CR22","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1086\/302287","volume":"64","author":"M Gibbs","year":"1999","unstructured":"Gibbs, M.  et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am. J. Hum. Genet. 64, 776\u2013787 (1999).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrurol2012257_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1086\/432377","volume":"77","author":"J Xu","year":"2005","unstructured":"Xu, J.  et al. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am. J. Hum. Genet. 77, 219\u2013229 (2005).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrurol2012257_CR24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.gde.2010.03.012","volume":"20","author":"JS Varghese","year":"2010","unstructured":"Varghese, J. S. & Easton, D. F. Genome-wide association studies in common cancers\u2014what have we learnt? Curr. Opin. Genet. Dev. 20, 201\u2013209 (2010).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"BFnrurol2012257_CR25","doi-asserted-by":"crossref","unstructured":"The Breast Cancer linkage Consortium. Cancer risks in BRCA2 mutation carriers. J. Natl Cancer Inst. 91, 1310\u20131316 (1999).","DOI":"10.1093\/jnci\/91.15.1310"},{"key":"BFnrurol2012257_CR26","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1158\/1078-0432.CCR-07-5237","volume":"14","author":"AJ Willems","year":"2008","unstructured":"Willems, A. J.  et al. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation. Clin. Cancer Res. 14, 2953\u20132961 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrurol2012257_CR27","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/sj.bjc.6604132","volume":"98","author":"A Mitra","year":"2008","unstructured":"Mitra, A.  et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br. J. Cancer 98, 502\u2013507 (2008).","journal-title":"Br. J. Cancer"},{"key":"BFnrurol2012257_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/sj.bjc.6604453","volume":"99","author":"SA Narod","year":"2008","unstructured":"Narod, S. A.  et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br. J. Cancer 99, 371\u2013374 (2008).","journal-title":"Br. J. Cancer"},{"key":"BFnrurol2012257_CR29","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/sj.bjc.6605822","volume":"103","author":"SM Edwards","year":"2010","unstructured":"Edwards, S. M.  et al. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br. J. Cancer 103, 918\u2013924 (2010).","journal-title":"Br. J. Cancer"},{"key":"BFnrurol2012257_CR30","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1158\/1940-6207.CAPR-10-0397","volume":"4","author":"H Thorne","year":"2011","unstructured":"Thorne, H.  et al. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev. Res. 4, 1002\u20131010 (2011).","journal-title":"Cancer Prev. Res."},{"key":"BFnrurol2012257_CR31","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s001090050162","volume":"75","author":"S Sigurdsson","year":"1997","unstructured":"Sigurdsson, S.  et al. BRCA2 mutation in Icelandic prostate cancer patients. J. Mol. Med. 75, 758\u2013761 (1997).","journal-title":"J. Mol. Med."},{"key":"BFnrurol2012257_CR32","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/jnci\/djm005","volume":"99","author":"L Tryggvad\u00f3ttir","year":"2007","unstructured":"Tryggvad\u00f3ttir, L.  et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J. Natl Cancer Inst. 99, 929\u2013935 (2007).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrurol2012257_CR33","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-09-2871","volume":"16","author":"DJ Gallagher","year":"2010","unstructured":"Gallagher, D. J.  et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin. Cancer Res. 16, 2115\u20132121 (2010).","journal-title":"Clin. Cancer Res."},{"key":"BFnrurol2012257_CR34","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/1098-2264(2000)9999:9999<::AID-GCC1090>3.0.CO;2-U","volume":"30","author":"H Gr\u00f6nberg","year":"2001","unstructured":"Gr\u00f6nberg, H.  et al. BRCA2 mutation in a family with hereditary prostate cancer. Genes Chromosomes Cancer 30, 299\u2013301 (2001).","journal-title":"Genes Chromosomes Cancer"},{"key":"BFnrurol2012257_CR35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/sj.onc.1201554","volume":"16","author":"C Li","year":"1998","unstructured":"Li, C.  et al. Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene 16, 481\u2013487 (1998).","journal-title":"Oncogene"},{"key":"BFnrurol2012257_CR36","first-page":"4830","volume":"55","author":"J Gudmundsson","year":"1995","unstructured":"Gudmundsson, J.  et al. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12\u201313. Cancer Res. 55, 4830\u20134832 (1995).","journal-title":"Cancer Res."},{"key":"BFnrurol2012257_CR37","first-page":"3877","volume":"63","author":"DK Vanaja","year":"2003","unstructured":"Vanaja, D. K., Cheville, J. C., Iturria, S. J. & Young C. Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 63, 3877\u20133882 (2003).","journal-title":"Cancer Res."},{"key":"BFnrurol2012257_CR38","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1593\/neo.10726","volume":"12","author":"K Park","year":"2010","unstructured":"Park, K.  et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12, 590\u2013598 (2010).","journal-title":"Neoplasia"},{"key":"BFnrurol2012257_CR39","unstructured":"Prostate Cancer Canada. Prostate Cancer Canada\u2014Early Detection Guideline \n                    [online]\n                    \n                  , (2010)."},{"key":"BFnrurol2012257_CR40","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schr\u00f6der","year":"2009","unstructured":"Schr\u00f6der, F. H.  et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320\u20131328 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol2012257_CR41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1464-410X.2010.09648.x","volume":"107","author":"AV Mitra","year":"2011","unstructured":"Mitra, A. V.  et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int. 107, 28\u201339 (2011).","journal-title":"BJU Int."},{"key":"BFnrurol2012257_CR42","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock, I. F.  et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502\u20131512 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol2012257_CR43","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak, D. P.  et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513\u20131520 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol2012257_CR44","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/j.1464-410X.2011.10292.x","volume":"109","author":"DJ Gallagher","year":"2012","unstructured":"Gallagher, D. J.  et al. Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. BJU Int. 109, 713\u2013719 (2012).","journal-title":"BJU Int."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2012.257.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2012.257","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2012.257.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:52:34Z","timestamp":1684471954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrurol.2012.257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,15]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["BFnrurol2012257"],"URL":"https:\/\/doi.org\/10.1038\/nrurol.2012.257","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,15]]}}}